compound
-
BeiGene in-licenses two clinical-stage oncology compounds
BeiGene will collaborate with Janssen in phase III clinical trials in melanoma and explore additional solid tumor indications in solid tumors prevalent in China and Asia.
compound | 15 October 2011
-
FDA makes recommendation on investigational compound dapagliflozin
Bristol-Myers Squibb company and AstraZeneca reported the outcome of the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.…
compound | 20 July 2011
-
Boehringer Ingelheim’s lead hepatitis C compound moves into phase 3
Boehringer Ingelheim announced the study outline for the pivotal phase 3 clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and experienced patients with chronic genotype-1 …
compound | 04 April 2011
-
Phase 3 study of investigational compound Ipilimumab achieves primary endpoint
Bristol-Myers Squibb company announced that a clinical trial--known as study 024--of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 0…
compound | 22 March 2011
-
FDA accepts new drug application for investigational compound dapagliflozin
Marketing authorisation application for dapagliflozin also validated by European Medicines Agency
compound | 09 March 2011
-
S*BIO's fourth compound enters phase 1 clinical trial
A fourth novel, potential bestin-class compound discovered and developed by S*BIO has entered a phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory he…
compound | 21 January 2011
-
“Lost Chemistry†Database to Aid Pharma Research
Selected Organic Reactions Database (SORD) and Advanced Chemistry Development (ACD/Labs) are offering the first version of a compound and reaction library as a commercial database that is available for use with ACD/ChemFolder or ACD/Web Librarian. …
compound | 10 March 2010
-
PPD and Janssen Pharmaceutica to Develop Therapeutic Compounds
PPD has entered an agreement with Janssen Pharmaceutica to develop and commercialize two Phase II-ready therapeutic compounds – one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin stru…
compound | 11 January 2010
-
PPD to Spin off Compound Partnering Business
PPD has announced its decision to proceed with preparations to spin off its compound partnering business from its core contract research organization, or CRO, business. The spin-off will result in two independent public companies. The CRO business…
compound | 31 December 2009
-
Institut Pasteur Korea to Screen Pfizer Compound Library in Collaboration with DNDi
Institut Pasteur Korea and the Drugs for Neglected Diseases Initiative (DNDi) have entered into a collaborative agreement, centered on the use of Pfizer’s compound library. This is for the identification and development of safe, effective and affor…
compound | 16 December 2009
